サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1789551

抗肥満薬市場：薬剤クラス別、薬剤タイプ別、地域別

Anti-Obesity Drug Market, By Mechanism of Action, By Prescription/Non- prescription, And by Region

出版日
ページ情報
英文 170 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
抗肥満薬市場：薬剤クラス別、薬剤タイプ別、地域別
出版日: 2025年07月04日
発行: Coherent Market Insights
ページ情報: 英文 170 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗肥満薬市場は2025年に258億7,000万米ドルと推定され、2032年には825億5,000万米ドルに達すると予測され、2025年から2032年までのCAGRは18.01%で成長する見込みです。

レポート範囲 レポート詳細
基準年 2024 2025年の市場規模 258億7,000万米ドル
実績データ 2020年から2024年まで 予測期間 2025年から2032年
予測期間：2025年～2032年CAGR： 18.01% 2032年の価値予測 825億5,000万米ドル

肥満とは、一般的に体格が大きすぎることと定義されます。体格指数（BMI）30以上が、成人の肥満の通常の基準です。抗肥満薬は、体内のコレステロール値を下げることによって体重を減らすために使用される薬です。これらの薬剤は、食欲や摂食カロリーを調整することによって、人体の基本的な機能に影響を与えます。抗肥満薬は一般的に肥満の治療に用いられます。米国食品医薬品局（FDA）と欧州医薬品庁（EMA）は、肥満治療のためにいくつかの抗肥満薬を承認しています。

市場力学

肥満人口の増加と関連する慢性疾患の増加、過体重や肥満に対する懸念の増加、抗肥満薬に対する需要の増加、研究開発の増加、COVID-19の発生は、予測期間中に世界の抗肥満薬市場の成長を促進すると予想される主な要因です。例えば、2021年6月、米国FDAは、肥満症および/または少なくとも1つの体重関連疾患（高血圧やコレステロール、T2Dなど）を有する過体重の成人における慢性的な体重管理のために、カロリーを抑えた食事と身体活動の増加に追加して使用するセマグルチド2.4mgを承認しました。

さらに2021年1月、世界的ヘルスケア企業であるノバルティスは、ビマグルマブと呼ばれる治験薬の第II相試験の結果を発表しました。この薬剤は肥満症を適応症とする可能性を示しています。同薬は現在、ノバルティスのパイプラインで研究されています。

本調査の主な特徴

  • 本レポートでは、世界の抗肥満薬市場を詳細に分析し、2024年を基準年とした予測期間2025年～2032年の市場規模と年間平均成長率（CAGR%）を掲載しています。
  • さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案のマトリックスについて説明しています。
  • また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
  • 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の抗肥満薬市場における主要企業プロファイルを掲載しています。
  • 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
  • 世界の抗肥満薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
  • 利害関係者は、世界の抗肥満薬市場の分析に使用される様々な戦略マトリックスを通じて意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学、規制、動向分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析
  • 主な発展
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 合併と買収のシナリオ
  • 業界動向

第4章 世界の抗肥満薬市場、薬剤タイプ別、2020年～2032年

  • 処方薬
  • 市販薬（OTC）

第5章 世界の抗肥満薬市場、薬剤クラス別、2020年～2032年

  • GLP-1受容体作動薬
  • MC4R（メラノコルチン4受容体）作動薬
  • リパーゼ阻害剤
  • ノルアドレナリン作動薬およびセロトニン作動薬
  • 併用療法
  • ナトリウム-グルコース共輸送体-2（SGLT-2）阻害剤
  • 胆汁酸吸着剤
  • アミリン類似体
  • プラムリンタイド
  • その他（後期医薬品等）

第6章 世界の抗肥満薬市場、投与経路別、2020年～2032年

  • 経口
  • 非経口
  • その他（経皮）

第7章 世界の抗肥満薬市場、タイプ別、2020年～2032年

  • ブランド
  • ジェネリック

第8章 世界の抗肥満薬市場、性別、2020年～2032年

  • 男性
  • 女性

第9章 世界の抗肥満薬市場、年齢グループ別、2020年～2032年

  • 成人
  • 高齢者
  • 小児

第10章 世界の抗肥満薬市場、流通チャネル別、2020年～2032年

  • 小売薬局
  • オンライン薬局
  • 病院薬局

第11章 世界の抗肥満薬市場、地域別、2020年～2032年

  • 北米
      • 米国
      • カナダ
  • ラテンアメリカ
      • ブラジル
      • アルゼンチン
      • メキシコ
      • その他ラテンアメリカ
  • 欧州
      • ドイツ
      • 英国
      • スペイン
      • フランス
      • イタリア
      • ロシア
      • その他欧州
  • アジア太平洋
      • 中国
      • インド
      • 日本
      • オーストラリア
      • 韓国
      • ASEAN
      • その他アジア太平洋地域
  • 中東
      • GCC諸国
      • イスラエル
      • その他中東
  • アフリカ
      • 南アフリカ
      • 北アフリカ
      • 中央アフリカ

第12章 競合情勢

  • Novo Nordisk
  • GlaxoSmithKline
  • AstraZeneca
  • Pfizer
  • Merck & Co.
  • Sanofi
  • Amgen
  • Eli Lilly and Company
  • Johnson & Johnson
  • Takeda Pharmaceutical Company
  • Abbott Laboratories
  • Orexigen Therapeutics
  • Zafgen
  • Rhythm Pharmaceuticals
  • Currax Pharmaceuticals

第13章 アナリストの推奨事項

  • 機会
  • アナリストの見解
  • Coherent Opportunity Map

第14章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI2824

Anti-Obesity Drug Market is estimated to be valued at USD 25.87 Bn in 2025 and is expected to reach USD 82.55 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 25.87 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 18.01% 2032 Value Projection: USD 82.55 Bn

Obesity is commonly defined as having too much body mass. A body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several anti-obesity drugs to treat obesity.

Market Dynamics

Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive the growth of the global anti-obesity drug market during the forecast period. For instance, in June 2021, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity.

Moreover, in January 2021, Novartis, a global healthcare company, announced the results of its Phase II trial of an investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.

Key features of the study

  • This report provides in-depth analysis of the global Anti-Obesity Drug Market, and provides market size (USD Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Anti-Obesity Drug Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
  • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global anti-obesity drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Anti-Obesity Drug Market

Market Segmentation

  • Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Prescription Drugs
    • Over-the-Counter (OTC) Drugs
  • Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
    • GLP-1 Receptor Agonists
    • Semaglutide
    • Liraglutide
    • Tirzepatide
    • MC4R (Melanocortin-4 Receptor) Agonists
    • Setmelanotide
    • Lipase Inhibitors
    • Orlistat
    • Noradrenergic & Serotonergic Drugs
    • Phentermine
    • Diethylpropion
    • Phendimetrazine
    • Combination Therapies
    • Phentermine/Topiramate
    • Naltrexone/Bupropion
    • Others
    • Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
    • Empagliflozin
    • Canagliflozin
    • Bile Acid Sequestrants
    • Colesevelam
    • Amylin Analogs
    • Pramlintide
    • Others (Late Phase Drugs, etc.)
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Oral
    • Parenteral
    • Others (Transdermal)
  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Brand
    • Generic
  • Gender Insights (Revenue, USD Bn, 2020 - 2032)
    • Male
    • Female
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Adult
    • Geriatric
    • Pediatric
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Retail Pharmacies
    • Online Pharmacies
    • Hospital Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Novo Nordisk
    • GlaxoSmithKline
    • AstraZeneca
    • Pfizer
    • Merck & Co.
    • Sanofi
    • Amgen
    • Eli Lilly and Company
    • Johnson & Johnson
    • Takeda Pharmaceutical Company
    • Abbott Laboratories
    • Orexigen Therapeutics
    • Zafgen
    • Rhythm Pharmaceuticals
    • Currax Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Anti-Obesity Drug Market, By Drug Type
    • Global Anti-Obesity Drug Market, By Drug Class
    • Global Anti-Obesity Drug Market, By Route of Administration
    • Global Anti-Obesity Drug Market, By Type
    • Global Anti-Obesity Drug Market, By Gender
    • Global Anti-Obesity Drug Market, By Age Group
    • Global Anti-Obesity Drug Market, By Distribution Channel
    • Global Anti-Obesity Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Anti-Obesity Drug Market, By Drug Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Prescription Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Over-the-Counter (OTC) Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Anti-Obesity Drug Market, By Drug Class, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • GLP-1 Receptor Agonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Semaglutide
        • Liraglutide
        • Tirzepatide
  • MC4R (Melanocortin-4 Receptor) Agonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Setmelanotide
  • Lipase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Orlistat
  • Noradrenergic & Serotonergic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Phentermine
        • Diethylpropion
        • Phendimetrazine
  • Combination Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Phentermine/Topiramate
        • Naltrexone/Bupropion
        • Others
  • Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Empagliflozin
        • Canagliflozin
  • Bile Acid Sequestrants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

o Colesevelam

  • Amylin Analogs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
      • Pramlintide
  • Others (Late Phase Drugs, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Anti-Obesity Drug Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Transdermal)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Anti-Obesity Drug Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Brand
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Generic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Anti-Obesity Drug Market, By Gender, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Male
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Female
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Anti-Obesity Drug Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Anti-Obesity Drug Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Anti-Obesity Drug Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Novo Nordisk
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orexigen Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zafgen
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Rhythm Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Currax Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us